
    
      The purpose of this study is to investigate if RPL554 has an additive bronchodilator effect
      when administered in combination with standard of care bronchodilators in patients with
      COPD.This study investigates the pharmacodynamic effect of RPL554 using spirometry and whole
      body plethysmography compared to placebo, when administered in addition to a beta2 agonist
      (salbutamol), a muscarinic antagonist (ipratropium) or placebo.
    
  